CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...